World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
40440
World Ranking
12475
National Ranking
1173

Overview

Fiona H Blackhall is affiliated with the University of Manchester in the United Kingdom. Their research primarily focuses on lung cancer, with a significant emphasis on the understanding and treatment of various forms of this disease. Their work spans multiple fields of study, including Medicine and Biochemistry, Genetics and Molecular Biology, with subfields concentrating on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Epidemiology, and Cancer Research.

The scientist's research topics cover areas such as:

  • Lung Cancer Research Studies
  • Lung Cancer Treatments and Mutations
  • Neuroendocrine Tumor Research Advances
  • Cancer therapeutics and mechanisms
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Peptidase Inhibition and Analysis

Fiona H Blackhall has contributed to a range of recent scientific papers. These include:

  • "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer", 2023, New England Journal of Medicine
  • "The evolution of lung cancer and impact of subclonal selection in TRACERx", 2023, Nature
  • "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study", 2021, Journal of Thoracic Oncology
  • "Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study", 2023, Journal of Clinical Oncology
  • "The evolution of non-small cell lung cancer metastases in TRACERx", 2023, Nature

Their frequent co-authors include:

  • Colin R. Lindsay
  • Caroline Dive
  • Yvonne Summers
  • Raffaele Califano
  • Corinne Faivre-Finn

The venues where Fiona H Blackhall most often publishes are:

  • Lung Cancer
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research

Best Publications

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Tracking the Evolution of Non–Small-Cell Lung Cancer

    Mariam Jamal-Hanjani;Gareth A. Wilson;Nicholas McGranahan;Nicolai Juul Birkbak

  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

    Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani

  • Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

    Nicholas McGranahan;Rachel Rosenthal;Crispin T. Hiley;Crispin T. Hiley;Andrew J. Rowan

  • Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

    Matthew G Krebs;Robert Sloane;Lynsey Priest;Lee J Lancashire

  • Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer

    Jian Mei Hou;Matthew G. Krebs;Lee Lancashire;Robert Sloane

  • Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

    Cassandra L Hodgkinson;Christopher J Morrow;Yaoyong Li;Robert L Metcalf

  • Molecular analysis of circulating tumour cells—biology and biomarkers

    Matthew G. Krebs;Robert L. Metcalf;Louise Carter;Ged Brady

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

    James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  • Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

    Matthew G Krebs;Jian-Mei Hou;Robert Sloane;Lee J Lancashire

  • Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

    Jian-Mei Hou;Matthew G Krebs;Timothy H Ward;Robert Sloane

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel

  • Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report

    Richard S. Irwin;Cynthia L. French;Anne B. Chang;Kenneth W. Altman

  • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

    Frederick Arce Vargas;Andrew J.S. Furness;Andrew J.S. Furness;Isabelle Solomon;Kroopa Joshi;Kroopa Joshi

  • Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

    Benjamin J. Solomon;Dong Wan Kim;Yi Long Wu;Kazuhiko Nakagawa

  • Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

    Pasi A. Jänne;Michel M. van den Heuvel;Fabrice Barlesi;Manuel Cobo

  • Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

    Suresh S. Ramalingam;Fiona Blackhall;Maciej Krzakowski;Carlos H. Barrios

  • Activity of the Monocarboxylate Transporter 1 inhibitor AZD3965 in Small Cell Lung Cancer

    Radosław Polański;Cassandra L Hodgkinson;Alberto Fusi;Daisuke Nonaka

Frequent Co-Authors

Caroline Dive
Caroline Dive University of Manchester
Paul Lorigan
Paul Lorigan University of Manchester
Nick Thatcher
Nick Thatcher University of Manchester
Keith M. Kerr
Keith M. Kerr Aberdeen Royal Infirmary
Benjamin Besse
Benjamin Besse University of Paris-Saclay
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Tony Mok
Tony Mok Chinese University of Hong Kong
Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Alex Molassiotis
Alex Molassiotis Hong Kong Polytechnic University
Charles Swanton
Charles Swanton The Francis Crick Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education offers flexible ways to advance your medical career in the USA. For registered nurses hoping to specialize, rn to np bridge programs let you move from an associate’s degree into nurse practitioner roles. Many of these programs are designed for working professionals and offer coursework online.

Interested in helping patients achieve better health through nutrition? Consider an online dietitian degree. These programs cover essential topics in food science, community health, and clinical nutrition, preparing you for a growing field.

For those drawn to the business side of healthcare, it’s important to carefully research how to evaluate healthcare administration degree programs. Accreditation, faculty experience, and industry connections all play a vital role in the quality of your MHA program.

If you’re an RN without the flexibility for in-person requirements, search for programs like rn to bsn no clinical hours options. These allow nurses to earn a bachelor’s degree online, expanding career opportunities with minimal disruption to work or family life.

Best Scientists Citing Fiona H Blackhall

Trending Scientists